2 weeks ago
GSK (GSK) Stock Slides 3% Following $10.6B Nuvalent Acquisition Deal
GSK stock drops 3% after announcing $10.6B Nuvalent acquisition. Deal adds two late-stage lung cancer drugs awaiting FDA approval in 2026.
The post GSK (GSK) Stock Slides 3% Following $10.6B Nuvalent Acquisition Deal appeared first on Blockonomi.
Source: Blockonomi →Related News
- 58 minutes ago
Penguin Solutions (PENG) Stock Drops 1.29% Despite New NVIDIA Partnership
- 1 hour ago
CoreWeave (CRWV) Stock Drops 5% Following BattleBots AI Partnership Announcement
- 2 hours ago
Datavault AI Inc. (DVLT) Stock Dips 4.67% Despite WiSA’s Chinese Market Breakthr...
- 2 hours ago
Tech Sector Reels: Oracle (ORCL) Job Cuts, Micron (MU) Earnings, and Chipmaker S...
- 2 hours ago
Quantinuum (QNT) Stock Rallies 15% Following Trump’s Quantum Computing Initiativ...